"studyAcronym","studyTitle","rationale","uuid:ID","versionIdentifier","id"
"LZZT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","e71ea102-3566-4a6e-af02-aeda3e1d0b05","2","StudyVersion_1"
